AXL and lung adenocarcinoma: This combined treatment also decreased the AXL levels and gefitinib resistance in EGFR-mutant HCC827 lung adenocarcinoma cells, thereby increasing apoptosis, suppressing the EMT, and eliminating cancer-cell stemness [19].